|Mr. John Michael Climaco Esq., J.D.||Chairman, CEO & Pres||635.1k||N/A||1969|
|Mr. Christopher S. Downs CPA, CTP, FP&A||Chief Financial Officer||394.7k||N/A||1979|
|Dr. Sandra L. Silberman||Chief Medical Officer||213.9k||N/A||1956|
|Dr. Waldemar Priebe Ph.D.||Founder & Chairman of the Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Donald H. Picker||Chief Science Officer||N/A||N/A||1946|
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.
CNS Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.